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Altered energy metabolism is an established hallmark of cancer cells. 
Fructose-2,6-bisphosphate is an allosteric activator of glycolysis and its 
concentration in a cell is dictated by the 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatases (PFKFB1-4) family of bifunctional 
enzymes. The PFKFB family of enzymes are characterized by their 
different kinase:bisphosphatase activities and were originally determined 
to be tissue-specific. More recent data however suggest that multiple 
isoforms are co-expressed in both normal and neoplastic tissues. PFKFB4 
is highly expressed in human cancer, strongly induced by hypoxia, and 
required for the survival of cancer cells However, it remains unclear 
whether the kinase or phosphatase activity of human PFKFB4 dominates. 




recombinant PFKFB4 and, using this purified protein, found that PFKFB4 
has a kinase to phosphatase ratio of 4.1:1. We found that a novel small 
molecule inhibitor of PFKFB4 (5MPN) inhibited the kinase activity of 
PFKFB4 and further that the known PFKFB3 inhibitors (PFK15 and 
PFK158) inhibited PFKFB4 less efficiently than 5MPN. We conclude that 
PFKFB4 functions mainly as a kinase and that, given the co-expression of 
PFKFB3 and PFKFB4, targeting both PFKFB3 and PFKFB4 isoforms 
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Cancer cells have an altered glucose metabolism 
 
The reprogramming of energy metabolism is an established 
hallmark of cancer cells [1]. Neoplastic cells exhibit an increased rate of 
glycolysis relative to normal cells, even in the presence of oxygen (i.e. 
aerobic glycolysis) [2]. This phenomenon of altered glucose metabolism in 
cancer cells was first observed in the early 20th century by Otto Warburg 
and was later termed the Warburg Effect. There are a number of theories 
addressing the question as to why tumors cells have higher glucose 
uptake and utilization. 
 
Warburg theorized that the inability of an increased level of oxygen 
to inhibit the metabolism of glucose to lactate indicated that cancer cells 
had a defect in their mitochondria [3]. Although a few cancers have shown 
a genetic defect in key Krebs cycle enzymes, the evidence supporting 
 
Warburg’s theory regarding the glycolytic phenotype in cancers is very 
limited [4]. Whereas Warburg’s hypothesis involving mitochondrial defects 
as the cause of enhanced glycolysis in cancer cells may have been 
incorrect, mitochondrial dysfunction has been demonstrated to play a role 
1 
 
in cancer [4] and there is growing interest in targeting mitochondrial 
function in order to inhibit tumor growth. 
 
Another possible explanation for this phenomenon is that aerobic 
glycolysis provides the cancer cell with other metabolic requirements 
necessary for a thriving cancer cell [5]. For a cancer cell to grow and 
divide rapidly it requires an abundance of nucleotides, amino acids, and 
lipids. By increasing their glycolytic rate, cancer cells produce large 
amounts of the building blocks, such as glucose 6-phosphate, 
dihydroxyacetone phosphate, 3-phosphoglycerate, phosphoenolpyruvate 
and pyruvate that are used in the synthesis of these macromolecules [6]. 
 
It is clear that cancer cells alter their metabolism to a less efficient 
process in terms of energy production and that this switch offers an 
advantage to the cancer cell. This glycolytic phenotype has been 
confirmed in human studies through the use of positron emission 
topography in that cancer cells have higher glucose uptake than its 
surrounding normal cells. Additionally, it is clear that several different 
mechanisms exist that account for this increase in glycolytic flux, including 
















The 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase family of 
 




The enzyme phosphofructokinase-1 (PFK-1) is a key regulatory 
point in the glycolytic pathway. PFK-1 catalyzes the irreversible reaction of 
fructose-6-phosphate to fructose-1,6-bisphosphate and is able to respond 
to the energy needs of the cells [8]. For example, citrate and ATP inhibit 
PFK-1, while AMP activates its activity. The most potent allosteric 
activator of PFK-1 is fructose-2,6-bisphosphate (F-2,6-BP) which is able to 
overcome the inhibition caused by a high ATP concentration. F-2,6-BP 
levels are dictated by the 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB1-4) family of enzymes that catalyze the 
interconversion of fructose-6-phosphate (F6P) and F-2,6-BP. There are 
four family members that share the same overall enzyme structure, but 
differ in their kinase and bisphosphatase activities due to structural 
differences in the regulatory regions [9]. 
 
In addition to their kinetic properties, each member of the PFKFB 
family is characterized by its tissue-specific expression. PFKFB1 and 
PFKFB2 isoforms are reported to have similar kinase to bisphosphatase 
ratios of 1.8:1 and 1.2:2 and were originally described to be expressed in 
the cells of the liver/muscle and kidney/pancreas respectively [10,11]. 
There is less characterization of PFKFB1 that links to cancer, however it 
has been shown to be induced in proliferating cells [12]. Furthermore, this 
induction results in an increased glycolytic rate [12]. PFKFB2 is known to 
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be essential for the regulation of glycolysis in the heart and is regulated by 
adrenaline, insulin, anoxia and workload. Recent data suggests this 
isoform is co-expressed with other isoforms in normal body tissues and in 
tumors [9]. 
 
The most extensively studied family member is PFKFB3. PFKFB3 
is of particular interest due to its high kinase to bisphosphatase ratio of 
740:1 [13] and increased mRNA and protein expression in tumors relative 
to normal tissues [14]. Hypoxia inducible factor-1 (HIF-1) is commonly 
stabilized in cancer cells and causes an increase in transcriptional activity 
of the PFKFB3 gene [15]. Furthermore, phosphorylation enhances the 
kinase activity of PFKFB3 and is shown to be increased in a wide range of 
human cancer lines and correlates to increased cell proliferation in several 
cell lines, e.g. the COS7 kidney cell line [16]. This evidence, along with 
many other studies, has led to a surge of research into the 
characterization of PFKFB3 and examination of its potential as a cancer 
drug target. 
 
Similar to PFKFB1 and PFKFB2, PFKFB4 has been less 
extensively studied than PFKFB3. However, more recently several studies 
examined its enzymatic activity and role in cancer development. In 2005, 
Minchenko et al. demonstrated that PFKFB4 mRNA is overexpressed in 
breast and colon malignant tumors compared to matched normal tissues 
and that the expression of the gene is highly induced by HIF-1 [17]. In 
2010, in a nonbiased RNA interference screen to identify genes important 
to the survival of brain cancer stem-like cells 
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(CSCs), PFKFB4 was identified as vital to the maintenance of brain CSCs 
and, thus a promising target in glioblastoma treatment [18]. A second 
nonbiased study further highlighted the role of PFKFB4 on cancer survival. 
Using siRNA-mediated gene silencing of several hundred metabolic 
proteins in three metastatic prostate cancer cell lines, Ros et al. identified 
PFKFB4 as a requirement for prostate cancer cell survival [19]. These 
three studies have drawn attention to the importance of PFKFB4 to cancer 
growth and led to growing interest in the development of inhibitors of 
PFKFB4 as possible anti-cancer agents. 
 
 
The kinase to bisphosphatase ratio of PFKFB4 is under investigation 
 
Although the requirement of PFKFB4 for the survival of a wide 
range of cancer types has been demonstrated by several studies, the 
exact function of PFKFB4 in the cell has not been fully established. Being 
a bifunctional enzyme, the balance between its kinase and 
bisphosphatase activities dictates its contribution to the concentration of F-
2,6-BP in a cell and thus to the regulation of glycolysis. If PFKFB4 has a 
higher bisphosphatase activity than kinase activity, then its expression 
would cause the concentration of F-2,6-BP in a cell to decrease, 
negatively impacting the allosteric activation of PFK-1, and increasing flux 
through the oxidative pentose phosphate pathway. Conversely, if the 
kinase domain of PFKFB4 were higher, the increased F-2,6-BP caused by 
its expression would result in the allosteric activation of PFK-1 and 
increased glycolytic flux. Evidence from Ros et al. demonstrate that 
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PFKFB4 appears to function mainly as a bisphosphatase in prostate 
cancer cell lines. Conversely, Goidts et al. have demonstrated that 
PFKFB4 has more kinase activity in glioblastomas [18,19]. In addition, the 
direct examination of the relative kinase and bisphosphatase activities of 
PFKFB4 has, until now, been limited to experiments using enzyme purified 
from the rat testes. Our objective was to determine the relative kinase and 
bisphosphatase activities of human PFKFB4 and to then examine the 
effects of inhibition by small molecule inhibitors on PFKFB4 in comparison 
with effects on the PFKFB3 isoform. The ultimate goal of our studies is to 
investigate the PFKFB4 kinase domain as a potential target for the 
development of cancer therapies. 
 
 




A recent examination of PFKFB4 activity presented strong evidence 
that supports the hypothesis that the predominant activity of PFKFB4 in 
cancer cells is to synthesize F-2,6-BP [20]. The selective inhibition of 
PFKFB4 in six of seven examined cancer cell lines led to decreased F-
2,6-BP synthesis, glycolysis, and ATP production. In addition, over-
expression of PFKFB4 in each of these six cancer cell lines showed the 
converse effect of increasing production of F-2,6-BP, glycolysis, and ATP. 
These studies also showed that under hypoxic conditions, PFKFB4 was 
markedly induced (to a far greater extent than PFKFB3 protein levels) and 
siRNA-mediated knockdown PFKFB4 led to a significant increase in 
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apoptosis indicating that PFKFB4 may be required for the glycolytic 
response to hypoxia. PFKFB4 expression also strongly correlated with 
expression of the hypoxia marker, carbonic anhydrase IX, by 
immunohistochemistry in xenograft tumors. In contrast, there was no 
observed correlation between PFKFB3 expression and the expression of 
carbonic anhydrase IX. Although the differences between the functions of 
PFKFB3 and PFKFB4 have yet to be fully examined, it appears that 
PFKFB4 may perform a unique function in cancer cells that are especially 































































The TOPO-PFKFB4 plasmid was extracted from DH5- α cells. Primers 
were designed to incorporate restriction sites at the ends of PCR amplified 
PFKFB4 gene. The PCR product was subject to a restriction digest and 
ligation in order to complete the pET-24d-PFKFB4 construct and was then 
confirmed using DNA sequencing. The new construct was transformed 
into Rosetta-I cells in order to express protein. 
 
 
Protein Expression and Purification 
 
The transformation was plated on an Luria-Bertani (LB) agar plate 
(kanamycin 50 µg/ml). A colony was picked from the plate and grown in 10 
ml of LB media (kanamycin 50 µg/ml) at 37 C overnight (300 RPM). The 
10 ml overnight culture was used to inoculate 2 1 LB cultures (kanamycin 
50 µg/ml). The cultures were placed in a 37 C incubator (300 RPM) and 
the optical densities (OD) were checked hourly for absorbance at 600 nm. 
Once the OD reached 1 (approximately 6 hours), protein 
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expression was induced with 0.2 mM of β-D-1-thiogalactopyranoside 
(IPTG). The 1 L cultures were grown overnight at 14 C (300 RPM). The 
bacterial cultures were sonicated, then centrifuged at 25,000 RPM for 30 
minutes at 4 C. Then, protein was extracted from the bacterial pellet using 
a lysis buffer (50 mM Tris buffer pH 7.5, 200 mM NaCL, 20 mM imidazole, 
 
0.35 mM β-mercaptoethanol). The protein was added to nickel agarose 
beads, washed 3 times with a bash buffer (50 mM Tris, 300 mM NaCl, 1 
mM imidazole, 0.175 mM β-mercaptoethanol). The protein was eluted with 
an elution buffer (50 mM Tris, 300 mM NaCl, 200 mM imidazole, 
 







Bicinchoninic acid assay (BCA) reagents were prepared (Thermofisher, 
Rockford, IL) by combining 50 ul of reagent A with 1 ul of reagent B. Fifty 
µl per well was then added to a 96 well flat-bottom, clear plate (Falcon, 
San Jose, CA) . Four µl of sample was then transferred to the wells and 
the plate was incubated at 37 °C for 30 minutes after which absorbance 
was read at 560 nm and a standard curve was used to interpolate the 
concentration of the protein sample. 
 
 
SDS PAGE Electrophoresis and Coomassie Stain 
 
Equal volumes of eluent was added to loading buffer (BioRad, Hercules, 
CA) containing 10µl/ml β-mercaptoethanol and then heated at 98 °C for 5 
minutes and then loaded onto a 4-12% gradient SDS-polyacrylamide gel 
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(BioRad, Hercules, CA) and run for 60 minutes at 120 volts. The gel was 
then stained with Coomassie Brilliant Blue (BioRad, Hercules, CA) until 
the gel was a uniform blue color. The gel was then destained overnight in 






Purified recombinant human PFKFB3 was obtained from the lab of Dr. Lee 
Hong-Hwan [28]. In brief, the His-tagged PFKFB3 protein was expressed 
in Escherichia coli BL21(DE3) pLysS. The protein was purified using 





PFKFB4 protein was purified according to the method outlined in chapter 






Fructose-6-phosphate kinase activities of human recombinant PFKFB3 
and PFKFB4 were assayed using previously described methods wherein 
one unit of activity was defined as the amount of enzyme that catalyzes 
the formation of 1 μmol of F-2,6-BP per min [31]. 500 ng of PFKFB3 was 
assayed, while 5 µg of PFKFB4 was used for the reaction. Aliquots of the 
reaction mixture were removed at intervals, added to 0.1N NaOH and then 








F-2,6-BP content was measured using a coupled enzyme reaction 
following the method of Van Schaftingen et al. [33]. Briefly, aliquots from 
the kinase assay were neutralized to a pH of 7.2 using 1 M acetic acid and 
1 M Hepes. Then, they were incubated at 25 ᵒC for 2 min in 50mM Tris, 
2mM Mg2+, 1mM F6P, 0.15mM NAD, 10u/l PPi-dependent PFK1, 0.45 
kU/I aldolase, 5 kU/I triosephosphate isomerase, and 1.7 kI/I glycerol-3-
phosphate dehydrogenase. 0.5 mM pyrophosphate was added and the 
rate of change in absorbance (OD=339 nm) per min over five minutes was 
determined (see diagram below). A calibration curve using 0.1 to 1 pmol of 
F-2,6-BP (Sigma, St. Louis,MO) was used to calculate total F-2,6-BP 




































Figure 1. Flow diagram of the fructose-2,6-bisphosphate assay. The 
reaction mix contains the sample to be quantified for F-2,6-BP 
concentration, 50mM Tris, 2mM Mg2+, 1mM F6P, 0.15mM NAD, 10u/l 
PPi-dependent PFK1, 0.45 kU/I aldolase, 5 kU/I triosephosphate 
isomerase, and 1.7 kI/I glycerol-3-phosphate dehydrogenase, and 0.5 mM 
pyrophosphate. The rate of change of absorbance (OD=339 nm) per min 
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The bisphosphatase activities of human recombinant PFKFB3 and 
PFKFB4 were assayed using previously described methods wherein one 
unit of activity was defined as the amount of enzyme that catalyzes the 
formation of 1 μmol of F-6-P per min [33]. 10 µg of PFKFB3 and PFKFB4 
were assayed in the reaction. Aliquots of the reaction mixture were 
removed at intervals, added to 0.1N NaOH and then neutralized to a pH of 







PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one) is a PFKFB3 small 
molecule inhibitor derivative of 3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-
propen-1-one) and was obtained from the lab of Dr. Jason Chesney [41]. 
For the kinase assay, three concentrations of PFK15 were used, 0.1 µM, 1 






PFK158 is a second small molecule inhibitor of PFKFB3 derived from 





kinase assay, three concentrations of PFK158 were used, 0.1 µM, 1 µM, 








5MPN is a novel and unpublished inhibitor of PFKFB4 that was identified 
through the combination of computational modeling and receptor based in 
silico screening. For the kinase assay, three concentrations of 5MPN were 
used, 0.1 µM, 1 µM, and 10 µM. For the phosphatase assay of PFKFB4, 






















































PURIFCATION OF HUMAN PFKFB4 FROM E. COLI CELLS USING 










The four members of the PFKFB family were originally believed to 
be expressed in distinct tissues. The enzymes encoded by the PFKFB1, 
PFKFB2 and PFKFB4 genes were originally described by the tissue in 
which they were thought to be exclusively expressed; liver/muscle, heart, 
and testes respectively. Additionally, these three isoenzymes have been 
reported to have very similar kinase to bisphosphatase ratios [21]. The 
kinase to bisphosphatase ratio of the final member, PFKFB3, originally 
termed the placental PFK2 or ubiquitous PFK2 [22] is reported to be 
approximately 740:1 [13], substantially higher than that of the other three 
PFKFB family members. 
 
While the core structure of the PFKFB enzymes is highly 
conserved, the observed differences between the enzymatic activities of 
the different isozymes arise from structural variations in the terminal 
regions that are believed to cause regulatory effects on the catalytic 
15 
 
regions by altering their tertiary and quaternary conformations [22]. Since 
co-expression of several isoforms has been noted in multiple tissues, it 
has been suggested that each family member may have unique roles 
under different physiological conditions or have differing responses to 
specific stimuli [15]. 
 
Understanding the precise kinase and bisphosphatase activities of 
PFKFB4 is crucial for determining whether it may be a rational drug target 
for cancer therapy. Analysis of PFKFB4 enzymatic activity has thus far 
been limited to protein purified from rat testes. In 1991, Sakata et al. 
examined the enzymatic activity of PFKFB4 using protein purified from the 
rat testes and determined that its kinase domain has 4.1 times greater 
activity than its bisphosphatase domain [23]. Although there exists 97 
percent homology between the rat and human PFKFB4 sequence [24], 
human recombinant PFKFB4 protein has yet to be examined. In order to 
adequately examine the enzymatic activity of human PFKFB4, we first 
sought to prepare human recombinant PFKFB4. In this chapter, we 
describe our experiments that were used in the preparation and 








The human PFKFB4 protein was expressed in Rosetta-1 cells and 
 






The TOPO-PFKFB4 plasmid was extracted from DH5α cells. To 
construct a plasmid containing the PFKFB4 gene we first designed 
primers in order to incorporate restriction sites into the DNA for the 
purpose of cloning into our expression vector. The sense primer (Figure 
2a) was designed to incorporate a Nco1 restriction site into the 3’ end of 
the DNA insert. Additionally, an antisense primer (Figure 2b) was 
designed to incorporate a Xho1 restriction site into the 5’ end PFKFB4 
 
DNA insert. The PCR product was subject to a restriction digest and 
ligation in order to complete the pET-24d-PFKFB4 construct and was 
confirmed using DNA sequencing. These two restriction sites were chosen 
so that the PFKFB4 DNA insert could be inserted into the pET-24d 
expression vector with a His-tag at the c-terminus (Figure 3). Rosetta-I 
competent cells were transformed with the expression vector and then 
conditions for the optimal expression of the PFKFB4 protein were tested. 
Protein expression was induced with 0.5 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and then purified through affinity 
chromatography using a nickel-agarose column. 
 
The protein was further purified through gel filtration which 
separated our protein of interest from a similarly sized heat-shock protein 
(Figure 4). Gel filtration fractions containing the PFKFB4 protein were 
subjected to SDS-PAGE electrophoresis to check for protein expression 
and purity (Figure 5). The protein concentration was determined using the 






Figure  2:  Designing  primers  to  incorporate  PFKFB4  DNA  into 
 
expression vector: a. Sense primer designed to incorporate a NcoI 
restriction site into the PFKFB4 DNA insert, b. Antisense primer designed 




















































Figure 3: pET-24d expression vector construct designed to include 
 
PFKFB4 DNA insert and a His-tag. The restriction sites NcoI and XhoI 
were chosen because they allowed the PFKFB4 insert to be incorporated 
into the plasmid with a His-tag at the C terminus and a few amino acids 






















































Figure  4.  Chromatogram  showing  the  gel  filtration  fractions  that 
 
yielded PFKFB4. The protein was purified through gel filtration to 
separate it from the heat shock protein that is close in size to PFKFB4. 

























































Figure 5. Coomassie stain of PFKFB4 protein on 4-20% SDS PAGE 
 
gel. After the protein was purified through gel filtration, fractions 23-29 
 
























































In order to adequately examine the function of human PFKFB4, we 
first set out to prepare recombinant human PFKFB4. After obtaining a 
human TOPO-PFKFB4 DNA construct, our first goal was to isolate the 
PFKFB4 gene using restriction digestion and then ligating the DNA into a 
pET-24d expression vector. This expression vector contains a c-terminal 
His-Tag sequence. The effect of the His-tag on the three dimensional 
folding and activity has not been explored, but its addition is crucial for 
purifying the PFKFB4 protein from a whole cell lysate using nickel-agarose 
column. After purifying the PFKFB4 protein using affinity chromatography, 
we further purified our product using gel filtration. The protein purity was 
assessed using SDS-PAGE electrophoresis and the gel was stained with 
Coomassie brilliant blue. A prominent protein band was visible at ~ 55 kD 
which is the reported size of the PFKFB4 protein, with no evidence of 
contaminating protein in any of the fractions. Thus, our experiments 
resulted in the purification of recombinant PFKFB4 protein for subsequent 





































Enzymes are proteins that catalyze chemical reactions. For single-
step reaction, according to the law of mass of action, the rate of the 
reaction is proportional the concentration of reactants. To characterize the 
relationship between substrate concentration (S) and reaction velocity (v), 






This relationship is known as the Michaelis-Menten equation and Vmax 
represents the maximum reaction rate of the system at saturating 
substrate concentrations. Furthermore, the Michaelis-Menten constant, 
Km, is the substrate concentration when the reaction rate is half the Vmax. 
Additionally, the value of Km is inversely related to the substrate’s affinity 




the rate will approach the Vmax more slowly. The relationship between 





















Reaction rates increase with increasing substrate concentrations, 
asymptotically approaching Vmax. Single-substrate reactions are also 
characterized by their turnover number (Kcat), which is described as the 
maximum number of substrate molecules converted to product per 
enzyme molecule per second. The relationship between Kcat, enzyme 









The units of Kcat is the rate of substrate converted to product per unit time 
per enzyme concentration. Typically, the units for substrate over enzyme 
concentration are dropped and only the units sec-1 are used. One 
constant commonly used to describe enzymatic activity is the specificity 




enzyme converts a substrate to product and is used to compare enzymes 
[45]. Theoretically, the specificity constant has an upper limit of 108-1010 
 
M and enzymes that approach this limit are considered more efficient. 
 
The enzyme constants, Vmax and Km, are determined experimentally 
by running a series of enzymatic assays at varying substrate concentrations 
and then measuring reaction rates. The Vmax and Km are then calculated by 
plotting reaction rate versus substrate concentration. Then, using nonlinear 
regression of the Michaelis-Menten equation, the enzyme constants can be 
calculated. However, before the use of computers, calculating enzyme 
constants involved graphical methods. One of these methods involves the 
linearization of the Michaelis-Menten equation through a double reciprocal 
plot or Lineweaver-Burk plot. This plot can be visualized through the following 




















From this plot, one can calculate the Km and Vmax constants through 
points where the line pass the axes. For instance, the x-intercept is equal 







Enzyme activity depends on a variety of factors, such as enzyme 
concentration, substrate concentration, pH of the reaction, temperature, 
and presence of activators or inhibitors [45]. Enzyme inhibitors are usually 
low molecular weight molecules that interact with the enzyme and change 
the activity of the enzyme by slowing down the reaction rate [45]. Inhibitors 
can bind to and inhibit a specific enzyme or can inhibit the enzyme 
nonspecifically through physical or chemical changes that denature the 
protein portion of the enzyme [46]. Based on how the enzyme interacts 
with the inhibitor, the inhibitor can be classified as either reversible if their 
interaction with the enzyme is non-covalent, or irreversible if the 
interaction is covalent. Furthermore, reversible inhibitors can be further 
classified as uncompetitive, competitive, or non-competitive. 
 
 
Competitive inhibitors usually mimic the enzyme’s natural substrate 
and compete with the substrate for access to the active site. Additionally, 
the inhibitor can only bind to the free enzyme and not the enzyme-
substrate complex. Therefore, by increasing the substrate concentration in 
the reaction mixture, the substrate can out-compete the inhibitor for the 
binding site. In contrast to competitive inhibitors, uncompetitive inhibitors 
only bind to the enzyme-substrate complex. And unlike competitive 
inhibition which reduces only the Km, in uncompetitive inhibition, both the 
Km and the Vmax are reduced. In noncompetitive inhibition, the inhibitor 
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binds to the enzyme at a site other than the active site and does not 
interfere with the binding of the substrate to the enzyme’s active site. 
 
Hence, the degree of inhibition is dependent only on the concentration of 
inhibitor added to the reaction and only the Vmax is reduced. The last type 
of reversible inhibition is a mixed type of inhibition. In this case, an 
inhibitor can bind to both the free enzyme as in competitive inhibition and 
to the enzyme substrate complex as in uncompetitive inhibition. This type 
of inhibition interferes with the binding of the substrate to the enzyme and 
reduces the effectiveness of the enzyme turnover [46]. Therefore, the Km 
is increased, but the Vmax is reduced. 
 
To evaluate the potency of an inhibitor the inhibition constant, Ki, is 
calculated [46]. The Ki is the concentration of enzyme required to produce 
half that maximum inhibition. Therefore, the lower the Ki value, then the 
lower the concentration of inhibitor needed to lower the reaction rate. The 
precise formula used to calculate the Ki value depends on the mode of 
inhibition (competitive, noncompetitive, uncompetitive, or mixed inhibition). 
However, once the mode of inhibition is determined, the Ki can be 

































BOTH PFKFB4 AND PFKFB3 HAVE A HIGHER KINASE THAN 
BISPHOSPHATASE ACTIVITY, BUT THE KINASE ACTIVITY OF 











F-2,6-BP is an allosteric activator of PFK-1 found in all mammalian 
tissues [25, 26]. The concentration of this signaling molecule is 
determined by the kinase activity of the PFKFB family of enzymes. The 
synthesis of F-2,6-BP from F-6-P is catalyzed by the N-terminal domain of 
the enzyme and is a sequential order reaction that involves a transfer of a 
phosphate from ATP to F-6-P [27]. Site-directed mutagenesis and 
modeling has provided evidence that the kinase domain of PFKFB is 
structurally similar to the mononucleotide-binding protein family which 
contain members such as adenylate kinase (AK) and ras [9]. Unlike AK, 
the kinase domain of PFKFB family members functions as a homodimer in 
which the two central six stranded β-sheets interact to form a continuous 
inter-monomer β –sheet (see figure below) [9]. But similar to AK, it is 
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proposed that ATP and F-6-P are trapped within the kinase domain and 
the mechanism is likely to include an induced fit feature [9]. 
 
Since PFKFB3 is the best characterized of the PFKFB family, in 
this study we decided to focus on comparing the enzymatic activity of 
PFKFB4 to that of PFKFB3. PFKFB3 has a significantly higher kinase to 
bisphosphatase ratio than PFKFB4 and there are several structural 
differences between the PFKFB3 and PFKFB4 that account for this 
difference. Structural and sequence variations between the two family 
members alter their catalytic and regulatory properties. PFKFB3 and 
PFKFB4 share a high sequence homology in their core kinase domain, but 
the surrounding N-terminal regulatory domains have important differences 
that alter their overall kinase functions [7]. The PFKFB3 isoform contains a 
β-hairpin N-terminal region that interacts with regions of the 
bisphosphatase domain affecting the function of the bisphosphatase 



























Figure 6: Folding of PFKFB3 protein. A ribbon diagram of the dimeric 
PFKFB3 structure is shown. ADP is bound to the kinase pocket (magenta) 
and F-6-P is shown bound to the kinase pocket. The regulatory domain is 
























































Additionally, sequence differences around the ATP and F-6-P binding 
sites decrease the flexibility of the C-terminus and its interference with the 
kinase catalytic region [28, 29]. Because of these structural features, the 
PFKFB3 isoform has a high kinase activity compared to the other 
isoforms. The Vmax of the kinase activity is reported as 142 mU/mg, the K-
m as 32 µM and kinase to bisphosphatase ratio as 710:1 for the human 
PFKFB3 isoform [13]. In contrast, the rat testes PFKFB4 isoform has been 
observed to have a kinase activity Vmax of 90 mU/mg, Km 85 µM and 
kinase to bisphosphatase ratio of 4.1:1. Although the crystal structure of 
human PFKFB4 has yet to be solved, the structure of PFKFB4 has been 






































Figure 7: Ribbon diagram of rat PFKFB4. The protein monomers are 
depicted as red and green. The ATPγS and PO4 ligands are shown in 
black. Arrrangement of the functional dimer about the crystallographic 
twofold axis of rotation. The protein monomers are colored red and green, 























































Sequence variations in PFKFB3 and PFKFB4 also contribute to 
regulatory differences between the two isoforms. In the PFKFB4 isoform, 
ATP binding must occur before F-6-P can bind making PFKFB4 more 
sensitive to ATP than F-6-P concentrations [30]. The sequence 
differences between PFKFB4 and the other isoforms affect how it is 
regulated. There is a mutation in the PFKFB4 isoform which destroys the 
recognition sequence for the cAMP-dependent protein kinase [31]. 
Additionally, unlike PFKFB3, PFKFB4 is not phosphorylated by any 
kinases in vivo [31]. PFKFB3 is phosphorylated by AMPK which activates 
its kinase activity [9]. 
 
Being bifunctional enzymes, all members of the PFKFB family have 
both a kinase and bisphosphatase activity. The bisphosphatase domain 
functions to catalyze the hydrolysis of F-2,6-BP to F-6-P and Pi and when 
the bisphosphatase activity is higher than the kinase activity, F-2,6-BP is 
converted to fructose-6-phosphate with a consequents of a decrease in 
the glycolytic flux. Additionally, enzymatic studies have shown that F-6-P 
is a non-competitive inhibitor of the reaction [36]. Furthermore, F-6-P is 
able to stabilize the intermediate by forming a complex that excludes H2O 
from the active site and preventing hydrolysis of the phosphoenzyme 
intermediate [37, 38]. 
 
Sequence differences between PFKFB3 and PFKFB4 also modify 
their bisphosphatase activities. The Vmax of the bisphosphatase activity is 
reported as 0.2 mU/mg, the Km for F-2,6-BP as 130 µM [13]. Although the 
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enzymatic activity of the human form of PFKFB4 has not been 
determined, the rat form of PFKFB4 is reported to have a Vmax of the 
bisphosphatase activity is reported as 22 mU/mg, the Km for F-2,6-BP is 
21 µM and kinase to bisphosphatase ratio as 4.1:1. 
 
Using the human recombinant PFKFB3 and PFKFB4 in the same 
kinase and bisphosphatase assays will provide evidence as to which 
domain is more active in PFKFB4. The direct examination of the relative 
kinase and bisphosphatase activities of PFKFB4 has, until now, been 
limited to experiments using enzyme purified from the rat testes. My 
objective here is to determine the bisphosphatase activity of human 
PFKFB4. This data will then provide evidence as to the importance of 








The kinase domain of recombinant human PFKFB4 has a maximum 
 
velocity of 25.2 ± 0.93 pmoles/minute 
 
We assayed the kinase and phosphatase activities of PFKFB4 
using purified recombinant human PFKFB4. The kinase activity was 
examined by measuring the rate of production of F-2,6-BP by PFKFB4 
from F6P as described by Van Schaftingen et al. using a range of 
substrate concentrations derived from the published rat PFKFB enzyme 
data (Figure 8). The Vmax was determined to be 25.2 ± 0.93 
pmoles/minute and the Km 356 ± 44.7 µM (95% confidence level). We 
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next measured the catalytic constant (Kcat), which measures the number 
of substrate molecules turned over per enzyme molecule per second and 
is defined as the Vmax per concentration of enzyme. The Kcat for 
PFKFB4 was calculated to be 5.03 ± 0.19 sec-1. In order to define the 
catalytic efficiency of the PFKFB4 enzyme, we also calculated the 






















































Figure 8. The kinetic data of PFKFB4 fits the Michaelis-Menten curve 
 
with an R2 = 0.99. The velocity of the kinase reaction was determined 
using a range of F-6-P concentrations (10, 42.5, 85, 170, 340, 680, 2000, 
and 6000 µM) and the kinetic constants were calculated from these data 
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The kinase domain of recombinant human PFKFB3 has a maximum 
 
velocity of 23.2 ± 0.82 pmoles/minute. 
 
In order to compare the kinase domain of PFKFB4 to that of the 
PFKFB3 isoform which is known to have a far higher kinase activity, we 
next examined the kinase activity of recombinant human PFKFB3. We 
used 0.5 µg of PFKFB3 protein and 6 concentrations of F-6-P to run the 
reactions and then assayed the reaction rate under each condition using 
an enzyme-coupled reaction that determined production formation for 
each condition (Figure 9). The Vmax was determined to be 23.2 ± 0.82 
pmoles/minute and the Km 10.2 ± 1.5 µM (95% confidence level). The 
Kcat was calculated to be 46.5 ± 1.63 sec-1, and the specificity constant to 




































Figure 9. The kinetic data of PFKFB3 fits the Michaelis-Menten curve 
 
with an R2 = 0.99. The velocity of the kinase reaction for PFKFB3 was 
determined under a range of F-6-P concentrations (1, 5, 10, 40, and 80 
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The bisphosphatase domain of recombinant human PFKFB4 has a 
 
maximum velocity of 11.7 ± 0.82 pmoles/minute. 
 
In order to examine the bisphosphatase activity of PFKFB4, purified 
recombinant PFKFB4 protein was assayed in a bisphosphatase assay. 
This assay measures the bisphosphatase activity by incubating purified 
PFKFB4 enzyme with increasing concentrations of F-2,6-BP and other 
reactants and then removing aliquots from the reaction at various time 
points. These aliquots were then assayed for F-2,6-BP in a subsequent 
enzyme-coupled reaction. Using the reported bisphosphatase activity 
reported in the literature of the rat form of PFKFB4, we optimized the 
conditions of the reaction. Ultimately, 5 concentrations of F-2,6-BP in the 
range of 5-160 µM were used to calculate the bisphosphatase activity of 
PFKFB4 (Figure 10). 
 
From the data extrapolated from the bisphosphatase assay, the 
maximum velocity and Michaelis-Menten constant were determined. The 
maximum velocity (11.7 ± 0.82 pmoles/minute) and Michaelis-Menten 
constant (18.2 ± 4.7 µM) at a 95% confidence level. Therefore, the Kcat for 








Figure 10. The bisphosphatase domain of PFKFB4 has a maximum 
 
velocity of 11.7 ± 0.82 pmoles/minute. Purified human recombinant 
PFKFB4 was assayed for bisphosphatase activity. For each reaction 10 
µg of PFKFB4 was assayed with a range of substrate concentrations (5, 
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The bisphosphatase domain of recombinant human PFKFB3 has a 
 
maximum velocity of 11.7 ± 0.82 pmoles/minute. 
 
We next similarly assayed the bisphosphatase activity of PFKFB3 
using purified recombinant PFKFB3 protein. From the data obtained from the 
bisphosphatase assay, the data points were fit to a Michaelis-Menten curve 
(figure 11) and the maximum velocity and Michaelis-Menten constant were 
determined. The maximum velocity was calculated to be 4.34 ± 0.59 
pmoles/minute and Michaelis-Menten constant found to be 69.1 ± 21.5 µM 
(95% confidence interval). The Kcat for the bisphosphatase domain of 







































Figure 11.The bisphosphatase domain of PFKFB3 has a maximum 
 
velocity of 4.34 ± 0.059 pmoles/minute. Purified human recombinant 
PFKFB4 was assayed for bisphosphatase activity. For each reaction, 10 
µg of PFKFB3 was assayed with increasing substrate concentrations (5, 
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Members of the PFKFB family have two enzymatic activities. This 
dual function dictates the concentration of an important allosteric activator 
of glycolysis by interconverting F-6-P and F-2,6-BP. Previously, PFKFB3 
has been thought to be the most important family member because of a 
sequence variation that diminishes its bisphosphatase activity allowing the 
enzyme to function almost exclusively as a kinase [9]. A variety of human 
cancer cell types show an over-expression of the PFKFB3 isoform, and, 
as a result, an increase in glycolytic flux to support their growth and 
energy requirements [40]. Recent data, however, indicate the PFKFB4 
isoform may perform an equally critical function in cancer cells [20]. 
 
The members of the PFKFB family of enzymes have been 
demonstrated to have varied kinase:bisphosphatase ratios [21]. A higher 
kinase activity suggests that the enzyme’s primary function is in the 
synthesis of F-2,6-BP, a major allosteric activator of PFK-1 and inhibitor of 
fructose-1,6-BP [21] and implies that it may perform an important function 
in cancer by increasing glycolysis to fulfill the energy requirements for the 
growing tumor. While this principle has been exploited in drug 
development through targeting PFKFB3, the enzymatic activities and thus 
the relevance of PFKFB4 have yet to be fully explored. 
 
To determine whether PFKFB4 functions predominantly as a 
kinase, we first sought to analyze its kinase activity. Using the published 
known rat PFKFB4 Michaelis-Menten constant of 85 µM [23] as a starting 
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point, we calculated kinase reaction rates using several substrate 
concentrations. Using this method, we calculated PFKFB4’s maximum 
velocity (25.2 ± 0.93 pmoles/minute) and Michaelis-Menten constant (356 
 
± 44.7 µM) at a 95% confidence level. 
 
We similarly examined the kinase activity of the PFKFB3 isoform. 
The published Michaelis-Menten constant for PFKFB3 is 32 µM [13] and 
we therefore varied the F6P concentrations from 1 to 80 µM in order to 
calculate the maximum velocity (23.2 ± 0.82 pmoles/minute) and 
Michaelis-Menten constant (10.2 ± 1.5 µM). 
 
Through our experiments, we determined the Kcat for the kinase 
domain of PFKFB4 to be 5.03 sec-1 and to be 1.17 sec-1 for the 
bisphosphatase domain. Therefore the kinase activity of human PFKFB4 
is 4.3 times that of the bisphosphatase activity (see table below). This ratio 
is very similar to the reported ratio for rat PFKFB4 that was reported as 
4.1:1 in the literature [23]. We also calculated the Kcat of the kinase and 
bisphosphatase domains of PFKFB3 which were determined to be 46.5 
sec-1 and .434 sec-1 respectively, giving human recombinant PFKFB3 a 
kinase:bisphosphatase ratio of 107:1 (see table below). 
Isoform PFKFB4 PFKFB3 
   
Kinase Activity (sec-1) 5.03 46.5 
   
Phosphatase Activity (sec-1) 1.17 .434 
   
Kinase:phosphatase ratio(sec-1) 4.3:1 107:1 







Our conclusion that PFKFB4 functions primarily as a kinase is further 
supported by the intracellular concentrations of F-6-P and F-2,6-BP. Since 
the concentration of F-6-P, the substrate for the kinase domain, is >10,000 
fold the concentration of F-2,6-BP, the substrate for the phosphatase 
domain (e.g. MCF-7 cells: F6P, 50±24 nmol/mg protein [48]; F2,6BP, 
2.97±.21 pmol/ mg protein [49]), then the kinase activity should be 
dominant. 
 
Since 2012, the data supporting the development of cancer 
therapeutics targeting PFKFB4 has been significantly expanded. PFKFB4 
has been found to be critical for cancer cell survival in gliomas and 
prostate cancer and breast cancer, colon cancer, and lung cancer lines 
[18-20]. Furthermore, in 2014 Chesney, Clark et al. showed that PFKFB4 
over-expression in 6 different cancer cell lines increased F-2,6-BP 
production, ATP production, and glycolysis [20]. Although these studies 
indicate that PFKFB4 functions predominantly as a kinase, a direct 
measurement of human PFKFB4 recombinant protein had not previously 
been conducted. Therefore, this present study includes a direct 
measurement of the kinase and bisphosphatase activities of PFKFB4. By 
determining biochemically that the kinase domain has a 4.3 times greater 
activity than the bisphosphatase domain, our data strongly support the 
development of small molecule inhibitors targeting the kinase domain of 
PFKFB4 to decrease the intracellular concentration of F-2,6-BP and 

















PFKFB4 IS INHIBITED BY THE SMALL MOLECULE INHIBITOR 5MPN 








A common characteristic of most human cancers is an increased 
glucose uptake and metabolism due to genetic alterations that increase 
the expression of many glycolytic enzymes [5]. The PFKFB family of 
enzymes (PFKFB1-4) synthesize F-2,6-BP which activates PFK-1, a key 
glycolytic enzyme that catalyzes the conversion of fructose-6-phosphate to 
fructose-1,6-bisphosphate. 
 
Of the PFKFB family, the PFKFB3 family member has been 
extensively studied. Research has shown that PFKFB3 expression is 
increased by hypoxia and a direct transcriptional target of HIF1α [38]. Not 
only is the expression level of PFKFB3 increased in most tumor types [39], 
but the heterozygous deletion of the Pfkfb3 gene has been shown to 
decrease levels of F-2,6-BP, glucose uptake, and glycolytic flux to lactate 
[40]. These data along with other studies demonstrated that PFKFB3 is a 
rational target for the development of anticancer therapies and a small 
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molecule inhibitor of PFKFB3 (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-
one, termed 3PO) was developed in 2008 [41]. Subsequently, derivatives 
of 3PO were screened from which one compound was used for further 
testing, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15). 
 
PFK15 was tested in vivo and in vitro and was shown to cause 
apoptosis in a leukemia cell line, have superior pharmacokinetic properties 
to 3PO, decrease growth in a Lewis Lung Carcinoma xenograft model and 
suppress 18F-FDG uptake by LLC xenografts [41]. Following the 
investigation of PFK15, another derivative of 3PO has now been 
developed, termed PFK158. This derivative is more potent than 3PO, has 
improved pharmacokinetic properties, and causes an approximately 80% 
inhibition of tumor growth in several xenograft tumor models [42]. PFK158 
is currently being tested in a phase 1 clinical trial in advanced cancer 
patients (clinicaltrials.gov #NCT02044861). 
 
Expression of the PFKFB4 family member has also been shown to 
be increased in multiple tumors, induced significantly by hypoxia [20] and 
critical for cancer cell survival. Genomic and siRNA-mediated deletion of 
PKFB4 has been found to cause a decrease in F2,6 BP, proliferation and 
lead to increased apoptosis. These data provide rationale for the 
development of inhibitors targeted against PFKFB4 and recently, a novel 
small molecule inhibitor of the PFKFB4 enzyme has been identified 
through in silico screening (termed 5MPN). 5MPN decreases F-2,6-BP 





administration in a mouse xenograft model has been found to decrease 
tumor growth in vivo. 
 
The co-expression of the PFKFB3 and PFKFB4 isoforms in multiple 
tumors makes it likely that targeting both the PFKFB3 and PFKFB4 
isoforms may be required in order to adequately suppress the glycolytic 
flux that is characteristic of tumor cell metabolism. Although it is clear that 
PFK15 and PFK158 target PFKFB3 and result in decreased tumor growth 
in vivo through a decrease in glucose uptake, it remains uncertain as to 
how specific these inhibitors are for PFKFB3 over the other PFKFB family 
members. Therefore, our objective is to assess the selectivity of the 
known inhibitors of PFKFB3, PFK15 and PFK158, as well as investigate 
inhibition of PFKFB4 and PFKFB3 by a novel PFKFB4 small molecule 
inhibitor, 5MPN. 
 
We sought to examine the effect of 5MPN on PFKFB4 activity in a 
kinase assay and additionally, examine the effect of the PFKFB3 
inhibitors, PFK15 and PFK158, on both the PFKFB4 and PFKFB3 
enzymes in order to determine their specificity for their targets and their 
effectiveness at blocking F-2,6-BP production. In addition to an 
examination of the effects of these inhibitors on the production of F-2,6-
BP, we chose to also examine the effect of these selective kinase 
inhibitors for PFKFB3 and PFKFB4 on the activity of the bisphosphatase 
in order to allow a more accurate measurement of the bisphosphatase 









PFK15 and PFK158 competitively inhibit PFKFB3 better than PFKFB4 
 
Several published inhibitors have been developed to target 
PFKFB3. We chose to examine PFK15 and PFK158 and assessed their 
effect on the activity of PFKFB3 and PFKFB4 with the aim of determining 
whether these inhibitors are more selective for PFKFB3 than PFKFB4. To 
analyze the data, Sigmaplot ranks the possible models of inhibition, 
competitive inhibition, non-competitive inhibition, and mixed inhibition, 
according to their coefficient of determination (R2) and Akaiki Information 
Criterion (AIC) values in order to select the model that best fit the data 
[43]. AIC is a technique that measures the goodness of fit of a statistical 
model and selects a model from a set of candidate models. The chosen 
model is the one that is expected to minimize the difference between the 
model and the truth. Given a data set, several possible models may be 
ranked according to their AIC value, and the model giving the lowest AIC 
value is selected as having the best fit for the data set [43]. Using the best 
model, we then compared the inhibition constants (Ki) to determine 
whether the drug better inhibits PFKFB3 or PFKFB4. 
 
Since 3PO, the parent compound to PFK15 and PFK158, is 
reported to show a mixed inhibition model, we hypothesized that PFK15 
and PFK158 would inhibit through the same mechanism. We examined 
increasing concentrations of PFK15 (100 nM, 1 µM, and 10 µM) in the 
kinase reaction with several substrate concentrations (5, 10, 40, 80, and 
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320 µM) and 500 ng of PFKFB3 and selected the best inhibition model. 
First, the models were ranked according to their R2 values. The 
competitive and mixed inhibition models shared the same R2 value of 0.93 
which was higher than the R2 value for noncompetitive inhibition model. 
Next, the AIC values were compared to select whether competitive or 
mixed inhibition better fit the data set. Given that the preferred model is 
the one with the lower AIC value, and that the competitive model had a 
value of 2.54 and the mixed model had a value of 3.42, then it is 
suggested that PFK15 inhibits PFKFB3 through a competitive inhibition 
model (Figures 12-13). Therefore, using the competitive inhibition model 







































Figure 12. PFK15 competitively inhibits PFKFB3 and the KI  is 2.1 ± 
 
0.59. After comparing possible models of the interaction between PFK15 
and PFKB3, competitive inhibition was concluded as the model of 
inhibition because it has the highest R2 value (0.93) and lowest AIC value 
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Figure  13.  The  Lineweaver-Burk  plot  also  suggests  that  PFK15 
 
competitively inhibits PFKFB3. The data points were also fit to a 
Lineweaver-Burk plot. This plot also suggests competitive inhibition as the 
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Similarly, we used the same concentrations of PFK15 to examine 
its affinity for PFKFB4 in the same kinase reactions we used to assay its 
kinase activity. Also to the kinase reaction, several concentrations of 
substrate (42.5 µM, 85 µM, 170 µM, 340µM, and 680 µM) and 5 µg of 
PFKFB4 were added. Again, we ranked the different models to select the 
one that best fits the data set. The noncompetitive inhibition model had the 
lowest R2 value (0.89) and competitive and mixed inhibition shared the 
same, higher R2 value (0.91). The AIC values were used to further rank 
the competitive and mixed inhibition models, which were 57.4 and 61.0 
respectively. Like PFKFB3, the AIC value for competitive inhibition is lower 
than that of the mixed inhibition model and is therefore the model that best 
fits the data set (Figures 14-15). According to the competitive model of 

































Figure 14. PFK15 competitively inhibits PFKFB4. After comparing 
possible models of the interaction between PFK15 and PFKB4, the 
competitive inhibition model had the highest R2 value (0.91) and lowest 
AIC value (57.4). Therefore, competitive inhibition was concluded as the 
best model of the interaction between PFKFB4 and PFK-15. Using this 













 50         
 
 45         
 
 40         
 








30         
 
25         
 






20         
 
         
 
 15         
 
 10         
 
 5         
 
 0         
 
 0 100 200 300 400 500 600 700 800 
 
    [substrate[ (µM)  
[PFK-15] µm 
 
        
 
 
Vmax = 43.4 I = 0  
  
Km = 62.9 I = 0.1 
 
Ki = 10.8 I = 1 
 





Figure  15.  The  Lineweaver-Burk  plot  also  suggests  that  PFK15 
 
competitively inhibits PFKFB4. The data points from the kinetic assay 
data used for the Michaelis-Menten curve were also fit to a Lineweaver-
Burk plot. This plot also suggests competitive inhibition as the model of 
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Since PFK158 is the PFKFB3 inhibitor that is currently being using 
in clinical trials, we chose to also examine the effect of PFK158 on 
PFKFB3 and PFKFB4. We used the exact methods used when analyzing 
the inhibition of PFK15 for PFKFB3 and PFKFB4. Mixed and competitive 
inhibition had and equal R2 value (0.87) that was higher than 
noncompetitive inhibition, but the AIC value for the competitive inhibition 
model was lower than the value for mixed inhibition; 38.0 and 41.6 
respectively. The data suggested that the competitive inhibition model 
best fit the data (Figures 16-17) and therefore, the KI value for PFK158 for 
PFKFB3 is 10.1 ± 6.0. For PFKFB4, the competitive, noncompetitive, and 
mixed models all shared the same R2 value, 0.99. However, the 
competitive inhibition model had the lowest AIC value, 41.5 than the other 
noncompetitive and mixed inhibition which were 44.8 and 45.1 
respectively. Thus, it is suggested that the competitive inhibition model 
best fit the PFKFB4 data (Figures 18-19) and the Ki value for PFKF158 























Figure 16. PFK158 competitively inhibits PFKFB3 and the KI is 10.1 ± 
 
6.0. Three models of inhibition, competitive, non-competitive, and mixed 
inhibition, were compared for the interaction between PFK158 and 
PFKB3. Competitive inhibition was concluded as the model of inhibition 
because it has the highest R2 value (0.87) and lowest AIC value (38). 
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Figure  17.  The  Lineweaver-Burk  plot  also  suggests  that  PFK158 
 
competitively inhibits PFKFB3.  The data points from the kinetic assay 
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Figure 18. PFK158 competitively inhibits PFKFB4 , however, with a KI 
 
value of 34.2 ± 14.6. Of the models of inhibition used to analyze the 
kinetic data generated from the interaction between PFK158 and PFKFB4, 
competitive inhibition best models the relationship. Competitive inhibition 
has both the highest R2 value (0.99) and lowest AIC value (38). Using this 
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Figure 19: PFK158 blocks PFKFB4 through competitive inhibition. A 
 
Lineweaver-Burk plot was also used to model the kinetic data from the 
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Although the PFKFB3 inhibitors, PFK15 and PFK158, also target 
PFKFB4, they do so with a much lower affinity. Therefore, we next elected 
to look at a novel PFKFB4 inhibitor, 5MPN to examine its effect on 
PFKFB4 and determine if it also inhibits PFKFB3. Different concentrations 
of 5MPN (0 µM, 100 nM, 1 µM, and 10 µM) were added to the kinase 
reaction with PFKFB4 in which we used 5 µg of PFKFB4 and 5 
concentrations of fructose-6-phosphate (10 µM, 85 µM, 340 µM, 680 µM, 
and 2 mM). Three models of inhibition were then ranked according to their 
R2 values. Competitive and mixed inhibition both had an R2 value of 0.98, 
while noncompetitive had a lower value of 0.97. The competitive model 
had the lower AIC value (-12.4) than the mixed model (-8.8). Accordingly, 
the data suggests that the competitive inhibition is the best model (figures 
20-21) and the Ki value for 5-MPN for PFKFB4 is 8.6 ± 1.9. However, 
when we added the same concentrations of 5MPN to the kinase reaction 
with PFKFB3, the error was so high with each of the three models that the 
data was unable to be interpreted suggesting that 5MPN does not inhibit 




















Figure 20.  5MPN competitively inhibits PFKFB4, and with a KI value 
 
of 8.6 ± 1.9, best inhibits PFKFB4. An inhibitor designed to selectively 
inhibit the substrate binding site of PFKFB4 was analyzed to determine 
the mode of inhibition. Of the models of inhibition, competitive inhibition 
best models the relationship between 5-MPN and PFKFB4. Competitive 
inhibition has both the highest R2 value (0.98) and lowest AIC value (-









 14      
 
 12      
 








8      
 






6      
 
      
 
 4      
 
 2      
 
 0      
 
 0 500 1000 1500 2000 2500 
 
   [Fructose-6-phosphate] (µM)   
 
 
Vmax = 16.9 I = 0  
  
Km = 642. I =  [5MPN] µm  









Figure  21.   The  Lineweaver-Burk  plot  also  suggests  competitive 
 
inhibition  for  the  interaction  between  PFKFB4  and  5-MPN.   A 
 
Lineweaver-Burke plot was also used to model the kinetic data from the 
 

























































Figure 22. 5MPN does not inhibit PFKFB3. An inhibitor designed to 
selectively inhibit the substrate binding site of PFKFB4 was also analyzed 
to determine its specificity for the PFKFB3 isoform. The Michaelis-Menten 























































Adding kinase inhibitors to the bisphosphatase reactions increased 
 




By previously testing the specificity of the PFKFB3 and PFKFB4 
inhibitors, we were able to identify that PFK-15 best inhibits PFKFB3 and 
5MPN best inhibits PFKFB4. Therefore, we added the highest 
concentrations (10 µM) of drug to the bisphosphatase reactions in order to 
more accurately calculate the bisphosphatase reactions and therefore the 
kinase to bisphosphatase ratios for both PFKFB4 and PFKFB3. For 
PFKFB4 we followed the some procedures previously outlined, except that 
we added 5MPN to the bisphosphatase reaction (Figure 23). The reaction 
rates for each substrate concentration curve fits the Michaelis-Menten 
equation at an R2 value of 0.99 As a result, the Vmax changed to 19.5 ± 
1.0 pmoles/second from 11.7 ± 0.8 pmoles/second and the Kcat changed 






























Figure 23. The addition of 5-MPN to the bisphosphatase assay for 
 
PFKFB4 increased the Vmax and Kcat. Inhibiting the kinase domain of 
PFKFB4 through the addition of 10 µM of 5-MPN to the bisphosphatase 
reaction increased the Vmax calculation to 19.5 ± 1.0 from 11.7 ± 0.8 
pmoles/sec and changed the Kcat calculation from 1.17 ± 0.1 sec-1 to 1.9 
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Subsequently, we repeated the bisphosphatase reaction for PFKFB3 
in the same manner as previously described, however, we added PFK15 to 
the reaction. We chose PFK15 instead PFK158 because it has a higher Ki 
value and therefore inhibits the kinase activity of PFKFB3 more efficiently. 
The calculated velocities for each substrate concentration adequately fit the 
Michaelis-Menten curve (R2 = 0.98, Figure 24). The addition of PFK15 to the 
reaction increased the Vmax calculation to 5.6 ± 0.4 from 4.3 ± 0.1 and 
changed the Kcat calculation from 0.43 ± 0.1 sec-1 to 
 

















































Figure 24.  The addition of PFK15 to the bisphosphatase assay for 
 
PFKFB3 increased the Vmax and Kcat. Inhibiting the kinase domain of 
PFKFB4 thought the addition of 10 µM of PFK15 to the reaction increased 
the Vmax calculation to 5.6 ± 0.4 from 4.3 ± 0.1 and changed the Kcat 
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Neoplastic transformation is characterized by an increase in 
glucose uptake and the conversion of glucose to lactate, even under 
aerobic conditions [2]. Glucose metabolism is regulated in part by the 
PFKFB family of enzymes. Of this family, the PFKFB3 and PFKFB4 
enzymes have been found to be induced by hypoxia, co-expressed in 
several cancer cell lines, and function mainly to synthesize F-2,6-BP. A 
family of small molecule inhibitors targeting the kinase domain of PFKB3 
(i.e. 3PO, PFK15, and PFK158) have been developed and in addition, a 
novel inhibitor of the PFKFB4 enzyme has recently been examined in vitro 
and in vivo and is under development. We sought to determine the effects 
of these inhibitors on the kinase activity of the PFKFB4 and PFKFB3 
enzymes. 
 
We first examined the effect of 5MPN on the kinase activity of 
PFKFB4. We found that 5MPN inhibits the kinase activity of PFKFB4 
through competitive inhibition. In order to determine the specificity of the 
effect of 5MPN on PFKFB4, we also chose to examine its effect on the 
PFKFB3 enzyme, which is known to be highly expressed in multiple 
cancer cell types. We found when 5MPN was added to the kinase assay 
of PFKFB3 that no detectable inhibition was observed. These results 





Inhibitors of the PFKFB3 enzyme have been developed and a 
clinical candidate, PFK158, is currently being tested in human subjects in 
a Phase I trial [42]. With the known co-expression of PFKFB3 and 
PFKFB4 isoforms in multiple tumor types, we next sought to measure the 
effects of PFK15 and PFK158 on recombinant PFKFB4’s kinase activity in 
comparison to its effect on PFKFB3. We found PFK15 and PFK158 
competitively inhibit the kinase activity of both PFKFB4 and PFKFB3, 
however, both drugs inhibit PFKFB4 at a much lower efficiency than they 
do PFKFB3. 
 
In order to characterize the interaction between the inhibitors and 
the enzymes, we then compared three different models of inhibition, 
competitive, non-competitive, and mixed. We found that all three small 
molecule inhibitors, PFK15, PFK158, and 5MPN, interacted with each 
isoform through competitive inhibition. However, we observed that the 
inhibitor designed to target the kinase domain of PFKFB4, 5MPN, had a 
minimal effect on the kinase activity of PFKFB3. Then, comparing Ki 
values (see table below), we identified that PFK15 and PFK158 to be 
effective PFKFB3 inhibitors and 5MPN to be only effective at inhibiting the 
kinase activity of PFKFB4. Interestingly, we found that PFK15 was more 












   Ki VALUES  
 
      
 
   PFKFB4  PFKFB3 
 
       
 Small 5MPN 8.6  N/A 
 




     
 PFK15 10.2  3.26 
 
      
 
  PFK158 20.9  9.05 
 




The Vmax increased to 19.5 ± 1.0 pmoles/minute from 11.7 ± 0.8 
pmoles/minute and the Kcat changed to 1.9 ± 0.1 sec-1 from 1.17 ± 0.1 
sec-1 We additionally found that inhibition of PFKFB4 by 5-MPN resulted 
in an increase in Vmax of the bisphosphatase activity (to 19.5 ± 1.0 
pmoles/second from 11.7 ± 0.8 pmoles/second) and changed the Kcat 
calculation to 1.9 ± 0.1 sec-1 from 1.17 ± 0.1 sec-1 We hypothesized that, 
due to the manner in which F-2,6-BP is synthesized, it is possible that 
contaminating ATP could be affecting the bisphosphatase reactions. If this 
were true, then the addition of kinase inhibitors should increase both the 
Vmax and Kcat for both PFKFB3 and PFKFB4. We previously showed that 
PFK15 best inhibits PFKFB3 and 5-MPN is the most potent inhibitor of 
PFKFB4. Therefore, using these drugs in the bisphosphatase reaction 
should allow us to better isolate the bisphosphatase domains and more 
accurately analyze the bisphosphatase activities for both enzymes. 
 
Without the inhibition of the kinase domain, then, in the presence of 
ATP, the reaction rate of the bisphosphatase domain appeared slower 




activity that was measured as a result caused the kinase to 
bisphosphatase ratio to drop from 4.1:1 as originally calculated to 2.7:1 
(see table below). 
 
 
Isoform PFKFB4 PFKFB4 + 
  5MPN 
   
Kinase Activity (sec-1) 5.03 5.03 
   
Phosphatase Activity (sec-1) 1.17 1.9 
   
Kinase:phosphatase ratio(sec-1) 4.3:1 2.7:1 
   
 
 
This phenomenon also held true for PFKFB3. Upon the addition of PFK15, 
the bisphosphatase reaction had a higher Vmax and Kcat. The Vmax 
increased to 5.6 ± 0.4 from 4.3 ± 0.1 and Kcat from 0.43 ± 0.1 sec-1 to .56 
± 0.04 sec-1 (see table below). As a result, the activity ratio also 
decreased from 107:1 to 83:1. Although the activity ratio for PFKFB4 was 
lower than originally calculated, its kinase activity is still higher than its 
bisphosphatase activity which highlights its importance to developing 
cancer-specific therapies. 
 
Isoform  PFKFB3 PFKFB3 + 
   PFK15 
    
Kinase Activity (sec-1)  46.5 46.5 
    
Phosphatase Activity (sec-1)  .434 .56 
    
Kinase:phosphatase ratio(sec-1)  107:1 83:1 
    
 72   
 
Based on our observations, the small molecule inhibitors of 
PFKFB3 and PFKFB4 show selective effects against their targets. The 
PFKFB3 and PFKFB4 isoforms are co-expressed in a large number of 
tumor types and our findings suggest that combinations of inhibitors of 





































































Comparing and contrasting normal cells to cancer cells is important 
in identifying differences in cancer cell characteristics that can be 
potentially exploited. Inhibition of PFKFB3 has shown a lot of promise both 
in vivo and in vitro and a clinical trial using a PFKFB3 inhibitor, PFK158, 
has recently begun. However, because of its undetermined kinase to 
bisphosphatase ratio, PFKFB4 has been less studied. Recent data has 
demonstrated that PFKFB4 may play a more important role in cancer 
development than previously believed. Our study has shown biochemically 
that the kinase domain of PFKFB4 has greater activity than its 
bisphosphatase domain and, in addition, has demonstrated that a novel 
PFKFB4 inhibitor, 5MPN, specifically targets the PFKFB4 family member. 
Additionally, this study has shown evidence that the current PFKFB3 
inhibitors are more specific to PFKFB3 than PFKFB4. Since PFKFB3 and 
PFKFB4 are co-expressed in a majority of cancers, the use of drugs to 
target both PFKFB3 and PFKFB4 in human cancers may prove to be a 




















Understanding the effects of 5MPN in vitro and in vivo 
 
5MPN is a newly developed small molecule inhibitor of PFKFB4 
and still under active investigation. We intend to further determine its 
efficacy in vivo and in vitro. We will examine the effects of 5MPN on 
normal cells in comparison to transformed cells and examine its effects on 
F-2,6-BP production, glucose uptake, glycolysis, and ATP production. 
Finally, we will perform in vivo toxicology studies and examine the effects 
of 5MPN on xenograft growth in mice. 
 
How other isoforms affected by PFKFB3 and PFKFB4 inhibitors 
 
 
Although PFKFB3 and now PFKFB4 have been examined in 
several studies, more research is necessary to fully understand how the 
members of this family of enzymes function and interrelate. In future 
studies, we intend to examine the effects of these small molecule 
inhibitors on PFKFB1 and PFKFB2. 
 
Further examination of the bisphosphatase activites of the PFKFB3 
 




Our initial results examining the bisphosphatase activity of both 
PFKFB3 and PFKFB4 yielded interesting results. However, a hurdle we 
have faced in the further examination of this activity has been a limited 
supply of F-2,6-BP, which is currently not available for purchase. 
 
We intend to synthesize F-2,6-BP, in order to label it with 32Pi and 
then use scintillation to measure the production of product over time 
instead of the complicated enzyme coupled reaction we have relied on for 
these studies . This method would greatly simplify the analysis of the 
bisphosphatase activity of the members of this family of enzymes and 



















































[1] Hanahan, Douglas, and Robert A. Weinberg. "Hallmarks of Cancer: 
The Next Generation." Cell 144.5 (2011): 646-74.  
 
[2] Warburg, O. "On the Origin of Cancer Cells." Science 123.3191 (1956): 
309-14.  
 
[3] Koppenol, Willem H., Patricia L. Bounds, and Chi V. Dang. "Otto 
Warburg's Contributions to Current Concepts of Cancer Metabolism."   
Nature Reviews Cancer 11.8 (2011): 618.  
 
Boland, Michelle L., Aparajita H. Chourasia, and Kay F. Macleod. 
"Mitochondrial Dysfunction in Cancer." Frontiers in Oncology 3 (2013): 
3:292. 
 
[5] Heiden, M. G. Vander, L. C. Cantley, and C. B. Thompson. 
"Understanding the Warburg Effect: The Metabolic Requirements of Cell 
Proliferation." Science 324.5930 (2009): 1029-033.  
 
[6] Lopez-Lazaro, Miguel. "The Warburg Effect: Why and How Do Cancer 
Cells Activate Glycolysis in the Presence of Oxygen?" Anti-Cancer Agents 
in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-
Cancer Agents) 8.3 (2008): 305-12.  
 
[7] Yalcin, Abdullah, Sucheta Telang, Brian Clem, and Jason Chesney. 
"Regulation of Glucose Metabolism by 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatases in Cancer." Experimental and Molecular Pathology   
86.3 (2009): 174-79.  
 
[8] Weber, George. "Enzymology of Cancer Cells." New England Journal 
of Medicine 296.10 (1977): 541-51.  
 
[9] Rider, Mark H., Luc Bertrand, Didier Vertommen, Paul A. Michels, Guy 
G. Rousseau, and Louis Hue. "6-Phosphofructo-2-kinase/fructose-2,6-
bisphosphatase: Head-to-head with a Bifunctional Enzyme That Controls 
Glycolysis." Biochemical Journal 381.3 (2004): 561.  
 
[10] Kountz, Paul D., M.raafat El-Maghrabi, and Simon J. Pilkis. "Isolation  
and Characterization of 6-phosphofructo-2-kinase/fructose-2,6-  
77 
 
bisphosphatase from Bovine Liver." Archives of Biochemistry and 
Biophysics 238.2 (1985): 531-43. 
 
[11] Kitamura, K and Uyeda, K. “The Mechanism of Activation of Heart 
Fructose-6-phosphate/fructose-2,6-bisphosphatase.” Journal of Biological 
Chemistry (1987): 679-681.  
 
[12] Ros, Susana, and Almut Schulze. "Balancing Glycolytic Flux: The 
Role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in Cancer 
Metabolism." Cancer & Metabolism 1.1 (2013): 8.  
 
[13] Sakakibara, R., M. Kato, N. Okamura, T. Nakagawa, Y. Komada, N. 
Tominaga, M. Shimojo, and M. Fukasawa. "Characterization of a Human 
Placental Fructose-6-Phosphate, 2-Kinase/Fructose- 2,6 - 
Bisphosphatase." Journal of Biochemistry 122.1 (1997): 122-28.  
 
[14] Bobarykina, Anastasia, Minchenko Dmytro, Opentanova Iryna, 
Moenner Michel, Caro Jaime, Esumi Hiroyasu, and Minchenko Oleksandr. 
“Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric 
and pancreatic cancer cell lines and expression of PFKFB genes in gastric 
cancers.” ACTA Biochimica Polinica; (2006): 789-799.  
 
[15] Minchenko, Oleksandr, Iryna Opentanova, and Jaime Caro. "Hypoxic 
Regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
Gene Family (PFKFB-1–4) Expression in Vivo." FEBS Letters 554.3 
(2003): 264-70.  
 
[16] Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, 
Yoshioka N, Bucala R, Koike T. “Phosphorylation of the 6-phosphofructo-
2-kinase/fructose 2,6- bisphosphatase/PFKFB3 Family of Glycolytic 
Regulators in Human Cancer.” Clinical Cancer Research (2005). 11: 
5784–5792.  
 
[17] Minchenko, O.h., A. Ochiai, I.l. Opentanova, T. Ogura, D.o. 
Minchenko, J. Caro, S.v. Komisarenko, and H. Esumi. "Overexpression of 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the Human 
Breast and Colon Malignant Tumors." Biochimie 87.11 (2005): 1005-010.  
 
[18] Goidts, V., J. Bageritz, L. Puccio, S. Nakata, M. Zapatka, S. Barbus, 
G. Toedt, B. Campos, A. Korshunov, S. Momma, E. Van Schaftingen, G. 
Reifenberger, C. Herold-Mende, P. Lichter, and B. Radlwimmer. "RNAi 
Screening in Glioma Stem-like Cells Identifies PFKFB4 as a Key Molecule 
Important for Cancer Cell Survival." Oncogene (2011): 3235-3243.  
 
[19] Ros, S., C. R. Santos, S. Moco, F. Baenke, G. Kelly, M. Howell, N. 
Zamboni, and A. Schulze. "Functional Metabolic Screen Identifies 6-




Regulator of Prostate Cancer Cell Survival." Cancer Discovery 2.4 (2012): 
328-43. 
 
[20] Chesney, J., Clark, J., Klarer, A., Imbert-Fernandez, Y., Lane, A., & 
Telang, S. “Fructose-2,6-Bisphosphate Synthesis by 6-Phosphofructo-2-
Kinase/Fructose-2,6- bisphosphatase 4 (PFKFB4) is Required for the 
Glycolytic Response to Hypoxia and Tumor Growth. Oncotarget (2014), 
5(16), 6670-6686.  
 
[21] Okar, David A., Alex J. Lange, Ànna Manzano, Aurèa Navarro-
Sabatè, lu s Riera, and Ramon Bartrons. "PFK-2/FBPase-2: Maker and 
Breaker of the Essential Biofactor Fructose-2,6-bisphosphate." Trends in 
Biochemical Sciences 26.1 (2001): 30-35.  
 
[22] Sakai A, Kato M, Fukasawa M. “Cloning of cDNA Encoding for a 
Novel Isoenzyme of Fructose-6-phosphate,2-kinase/fructose-2,6-
bisphosphatase From Human Placenta. Journal of Biochemistry (Tokyo) 
(1996). 119-505-511.  
 
[23] Sakata J, Abe Y and Uyeda K. “Molecular Cloning of the DNA and 
Expression and Characterization of Rat Ttestes Fructose-6-phosphate,2-
kinase:fructose-2,6- bisphosphatase. Journal of Biological Chemistry 
(1991). 266(24): 15764-15770.  
 
[24] Manzano, A., J.x Pérez, M. Nadal, X. Estivill, A. Lange, and R. 
Bartrons. "Cloning, Expression and Chromosomal Localization of a 
Human Testis 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
Gene." Gene 229.1-2 (1999): 83-89  
 
[25] Schaftingen, E. Van. "Fructose 2,6-bisphosphate, a Glycolytic Signal."  
Archives Of Physiology And Biochemistry 94.2 (1986): 151-59.  
 
[26] Hue L., Rider M. H. “Role of Fructose 2,6-bisphosphate in the Control 
of Glycolysis in Mammalian Tissues.” Journal of Biochemistry (1987). 
245:313–324.  
 
[27] Pilkis, S. "6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase: A 
Metabolic Signaling Enzyme." Annual Review of Biochemistry 64.1 (1995): 
799-835.  
 
[28] Kim, S.G. "Crystal Structure of the Hypoxia-inducible Form of 6-
Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A 
POSSIBLE NEW TARGET FOR CANCER THERAPY." Journal of 







[29] Michels, Paul, and Daniel Rigden. "Evolutionary Analysis of Fructose 
2,6-bisphosphate Metabolism." IUBMB Life (International Union of 
Biochemistry and Molecular Biology: Life) 58.3 (2006): 133-41.  
 
[30] Lee, Y.-H. "Tissue-specific Structure/Function Differentiation of the 
Liver Isoform of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase."   
Journal of Biological Chemistry 278.1 (2002): 523-30.  
 
[31] Hasemann, Charles A., Eva S. Istvan, Kosaku Uyeda, and Johann 
Deisenhofer. "The Crystal Structure of the Bifunctional Enzyme 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase Reveals Distinct 
Domain Homologies." Structure 4.9 (1996): 1017-029.  
 
[32] Sakata J, Abe Y and Uyeda K. “Molecular Cloning of the DNA and 
Expression and Characterization of Rat Testes Fructose-6-phosphate,2-
kinase:fructose-2,6- bisphosphatase.” Journal of Biological Chemistry 
(1991). 266(24):15764-15770.  
 
[33] Schaftingen, Emile, Beatrice Lederer, Ramon Bartrons, and Henri-
Gery Hers. "A Kinetic Study of Pyrophosphate: Fructose-6-Phosphate 
Phosphotransferase from Potato Tubers. Application to a Microassay of 
Fructose 2,6-Bisphosphate." European Journal of Biochemistry 129.1 
(1982): 191-95  
 
[34] Sakakibara, R., M. Kato, N. Okamura, T. Nakagawa, Y. Komada, N. 
Tominaga, M. Shimojo, and M. Fukasawa. "Characterization of a Human 
Placental Fructose-6-Phosphate, 2-Kinase/Fructose- 2,6 - 
Bisphosphatase." Journal of Biochemistry 122.1 (1997): 122-28.  
 
[35] Pilkis SJ, Regen DM, Stewart HB, Pilkis J, Pate TM, and El-Maghrabi 
MR. “ Evidence for Two Catalytic Sites on 6-phosphofructo-2- 
kinase/fructose 2,6- bisphosphatase. Dynamics of Substrate Exchange  
and Phosphoryl Enzyme Formation.” Journal of Biological Chemistry 
(1984); .259:949-957.  
 
[36] Tauler A, Lin K and Pilkis SJ. “ Hepatic 6-phosphofructo-2- 
kinase/fructose-2,6- bisphosphatase. Use of Site-directed Mutagenesis to  
Evaluate the Roles of His-258 and His-392 in Catalysis.” Journal of 
Biological Chemistry (1990). 265:15617-15622  
 
[37] Obach, M., A. Navarro-Sabate, J. Caro, X. Kong, J. Duran, M. 
Gomez, J. C. Perales, F. Ventura, J. L. Rosa, and R. Bartrons. "6-
Phosphofructo-2-kinase (pfkfb3) Gene Promoter Contains Hypoxia-
inducible Factor-1 Binding Sites Necessary for Transactivation in 






[38] Lin K, Li L, Correia J and Pilkis SJ. “ Arg-257 and Arg-307 of 6- 
phosphofructo-2-kinase/fructose-2,6- bisphosphatase Bind the C-2  
phospho Group of Fructose-2,6-bisphosphate in the Fructose-2,6- 
bisphosphatase Domain.” Journal of Biological Chemistry (1992). 267; 
19163-19171  
 
[39] Telang, S., A. Yalcin, A. L. Clem, R. Bucala, A. N. Lane, J. W. Eaton, 
and J. Chesney. "Ras Transformation Requires Metabolic Control by 6-
phosphofructo-2-kinase." Oncogene 25.55 (2006): 7225-234.  
 
[40] Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell 
R, Bucala R. “High Expression of inducible 6-phosphofructo-2-
kinase/fructose-2,6- bisphosphatase (iPFK-2; PFKFB3) in human 
cancers.” Cancer Research (2002). 62:5881–7.  
 
[41] Clem, B. F., J. O'neal, G. Tapolsky, A. L. Clem, Y. Imbert-Fernandez, 
D. A. Kerr, A. C. Klarer, R. Redman, D. M. Miller, J. O. Trent, S. Telang, 
and J. Chesney. "Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a 
Therapeutic Strategy against Cancer." Molecular Cancer Therapeutics 
12.8 (2013): 1461-470.  
 
[42] Telang S, O’Neal J, Tapolsky G, Clem B, Ker A, Imbert-Fernandez Y, 
Chesney J. “Discovery of a PFKFB3 inhibitor for phase I trial testing that 
synergizes with the B-Raf inhibitor vemurafenib.” Cancer and Metabolism 
(2014). 2(Suppl 1):P14  
 
[44] Dick  Mitchell.  Help  Topics  for  Exploratory  Enzyme  Kinetics.  
Sigmaplot. Systat, Inc. Web.  
 
[45] Orphardt, Charles . “Vitural Chembook.” Elmhurst College, 2009.  
 
[46] Mohan, Chandra, Kevin D. Long, and Manpreet Mutneja. "An 
Introduction to Inhibitors and Their Biological." EMB Millipore, 2013.  
 
[47] Beers, Melissa. “The Michaelis-Menten Model.” Wellesley College,  
2010.  
 
[48] Cohen JS, Lyon RC, Chen C, Faustino PJ, Batist G, Shoemaker M, 
Rubalcaba E and Cowan KH. Differences in phosphate metabolite levels 
in drug-sensitive and -resistant human breast cancer cell lines determined 
by 31P magnetic resonance spectroscopy. Cancer Res. 1986; 46(8):4087-
4090.  
 
[49] Imbert-Fernandez Y, Clem BF, O’Neal J, Kerr DA, Spaulding R,   
Lanceta L, Clem AL, Telang S and Chesney J. Estradiol stimulates 
glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem. 























Name: Jennifer Amanda Clark 
 
Education & Training: 
 
Institution Degree Years Field of Study  
Franklin B.A. 2005- Chemistry/Biology  
College  2009    
Franklin,      
Indiana      
Research and Job Experience:    
Position/Title  Year Employer/Location  
Associate Research 2009- ApoImmune   
Scientist  2010 Louisville, Ky  
   University of Louisville  
   Department of Medicine  
   Louisville, Ky  
Research Technician IV 2010-    
  2014    
Research Technician IV 2014- Mississippi Department of  Public 
  Present Health   











Donninger, H., N. Allen, A. Henson, J. Pogue, A. Williams, L. Gordon, S. 
Kassler, T. Dunwell, F. Latif, and G. J. Clark. "Salvador Protein Is a Tumor 
Suppressor Effector of RASSF1A with Hippo Pathway-independent 
Functions." Journal of Biological Chemistry 286.21 (2011): 18483-8491. 
 
Donninger, Howard, Thibaut Barnoud, Nick Nelson, Suzanna Kassler, 
Jennifer Clark, Timothy D. Cummins, David W. Powell, Sarah Nyante, 
Robert C. Millikan, and Geoffrey J. Clark. "RASSF1A and the Rs2073498 
Cancer Associated SNP." Frontiers in Oncology 1 (2011) 
 
Clark, Jennifer, Jessica Freeman, and Howard Donninger. "Loss of 
RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers 
Resistance to Chemotherapy." Molecular Biology International 2012 
(2012): 1-8. 
 
Klarer, Alden C., Julie O’Neal, Yoannis Imbert-Fernandez, Amy Clem, 
Steve R. Ellis, Jennifer Clark, Brian Clem, Jason Chesney, and Sucheta 
Telang. "Inhibition of 6-phosphofructo-2-kinase (PFKFB3) Induces 
Autophagy as a Survival Mechanism." Cancer & Metabolism 2.1 (2014): 2 
 
Chesney, J., Clark, J., Klarer, A., Imbert-Fernandez, Y., Lane, A., & 
Telang, S. (2014). Fructose-2,6-Bisphosphate synthesis by 6-
Phosphofructo-2-Kinase/Fructose-2,6- bisphosphatase 4 (PFKFB4) is 
required for the glycolytic response to hypoxia and tumor growth. 
Oncotarget, 5(16), 6670-6686. 
 
Donninger, H., Clark, J., Rinaldo, F., Nelson N., Barnoud T., Schmidt, 
ML., Hobbing, KR., Vos, MD., Sills, B., and Clark GJ. “The RASSF1A  
Tumor Suprressor Regulates XPA-Mediated DNA Repair.” Molecular Cell 
Biology (2014): 00202-14. 
 
National Meeting Presentations: 
 
Metabolism,  Diet  and  Disease  Conference:  Cancer  and  Metabolism-  
Poster Presentation: 
 
J. Clark, A. Lane, J. Chesney, S. Telang. “The Kinase Domain of PFKFB4 
is Required to Stimulate Glucose Metabolism and Growth in H460 Lung  
Adenocarcinoma Cells.” 
 
 
 
 
 
 
 
 
 
 
 
83 
